The size of the COVID-19 vaccine market across the seven major markets – the US, Germany, France, Italy, Spain, the UK, and Japan -will increase from $13.6bn in 2021 to $19.5bn in 2026 at a compound annual growth rate (CAGR) of 7.6% should annual vaccination be required, according to GlobalData. 

To find out more join us for a free webinar on 27.7.2021 at 4pm BST  

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

 COVID-19 vaccines based on mRNA technology dominate the 7MM in 2021 with a market share of 95.4% and $9.5bn in sales for Pfizer/BioNTech and $3.5bn for Moderna. 

GlobalData’s latest report, COVID-19 Vaccines: Global Drug Forecast and Market Analysis to 2026, models three different scenarios for the use of COVID-19 vaccines, since it is unclear how long protection from the current vaccines will last.  

In the first scenario, COVID-19 vaccines will be required annually, in the second scenario, annual vaccination will be assumed for the high-risk population of people 65 years of age and older, while everyone below 65 years of age will need a vaccine only every two years. In the third scenario, the high-risk population of people 65 years of age and older will receive a COVID-19 vaccine every two years, while everyone below 65 years will need a vaccine only every five years.  

In the latter two scenarios, market sales will fluctuate significantly over the forecast period to 2026, since most people in the 7MM (The US, Germany, France, Italy, Spain, the UK, and Japan) will receive a vaccine in 2021.   

The launch of a nanoparticle vaccine from Novavax and a recombinant protein vaccine from Sanofi and GlaxoSmithKline will decrease the market share of mRNA vaccines to 85% by 2026, but vaccines from Pfizer/BioNTech and Moderna will remain dominant.  

The market share of adenovirus vector-based vaccines from AstraZeneca and Johnson & Johnson is suspected to decrease due to their lower efficacy and lack of contract renewal in Europe. Barriers of growth will be low vaccination rates due to vaccine hesitancy and scepticism, which could be enhanced if more adverse events will be observed with COVID-19 vaccines.  

Key Opinion Leaders (KOL) interviewed by GlobalData for this report agreed that it will not be possible to know how long the protection from COVID-19 vaccines will last until the data comes in but emphasized that SARS-CoV-2 variants might make booster doses necessary. While some KOLs assume that protection will last for several years, others think that annual vaccination with COVID-19 vaccines will be necessary, like immunization against seasonal influenza. 

 

 

*7MM = The US, Germany, France, Italy, Spain, the UK, and Japan 

*5EU = Germany, France, Italy, Spain and the UK 

To find out more join us for a free webinar on 27.7.2021 at 4pm BST